Spruce Street Capital LP

NEW YORK, NY · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$629.0M2026 Q3
Positions39
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.64.0%

Spruce Street Capital LP reported 39 positions worth $629.0M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: KNSA (10.9%). Biggest move: new buy ENTX ($32.6M).

10 / 39 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 KNSAKiniksa Pharmaceuticals$68.5M10.89%918,070——+26.3%
▸ 2 LBRXLB Pharmaceuticals$53.9M8.56%1,404,779———
▸ 3 RLAYRelay Therapeutics$53.9M8.56%2,984,125——-4.3%
▸ 4 ANROAlto Neuroscience$42.8M6.80%1,676,558——+6.2%
▸ 5 ALKSAlkermes$38.4M6.11%948,471——+14.8%
▸ 6 ENTXEntera Bio$32.6M5.19%11,213,455——+2.7%
▸ 7 DNTHDianthus Therapeutics$31.2M4.97%354,816——+1.7%
▸ 8 SVRASavara$27.8M4.42%5,381,941——-10.1%
▸ 9 ZLABZai Lab$27.5M4.36%1,042,158——-10.9%
▸ 10 RLMDRelmada Therapeutics$26.1M4.14%6,912,191——+11.7%

Pro Feature

The remaining 29 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Spruce Street Capital LP hold as of Q3 2026?

Spruce Street Capital LP reported 39 positions worth $629.0M in its Q3 2026 13F filing. Largest positions: KNSA (10.9%), LBRX (8.6%), RLAY (8.6%), ANRO (6.8%) and ALKS (6.1%).

What did Spruce Street Capital LP buy in Q3 2026?

New positions: ENTX, OBX, SGMT, YARW and KRSA (9 in all). Added to: ZLAB, ALKS, SVRA, ANRO and RLMD (8 in all).

What did Spruce Street Capital LP sell in Q3 2026?

Spruce Street Capital LP reduced or sold out of no positions in Q3 2026.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.